Drug Trial Radar · NCT06810050
Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Apr 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
180
Actual
Start
Dec 18, 2024
Primary completion
Aug 30, 2025
Study completion Oct 30, 2025
Sponsor
- Lead sponsor
- CAGE Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if CGB-500 works to treat atopic dermatitis in participants ages 12 and older. The goal is also to learn about the safety of CGB-500. The main questions it aims to answer are: Does CGB-500 improve atopic dermatitis by decreasing the area affected and the severity of the lesions? What medical problems do participants have when taking CGB500? Researchers will compare CGB-500 to a placebo (a look-alike substance that contains no drug) to see if CGB-500 works to treat atopic dermatitis. Participants will: Take CGB-500 or a placebo every day for 8 weeks. Visit the clinic once every 2 weeks for the first month and at the end of 8 weeks. Keep a diary of when they use the product and complete a form about their symptoms including itching.
Conditions
- Atopic Dermatitis (AD)
Interventions
CGB-500 with 0.5% tofacitinibDrug
CGB-500 is a proprietary ointment formulation
CGB-500 Ointment with 1% tofacitinibDrug
CGB-500 is a proprietary ointment formulation
Vehicle (placebo)Drug
placebo ointment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerabilityTime frame: From enrollment to end of study at 8 weeks
- evaluate effectivenessTime frame: From enrollment to end of study at 8 weeks
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Center for Dermatology Clinical Research Inc.
Fremont, California
Ablon Skin Institute and Research Center
Manhattan Beach, California
TCR Medical Corporation
San Diego, California
Syrentis Clinical Research
Santa Ana, California
USA and International Research Inc.
Doral, Florida
FXM Clinical Research
Fort Lauderdale, Florida
Driven Research
Gables, Florida
FXM Clinical Research Miami, LLC
Miami, Florida
FXM Clinical Research Miramar, LLC
Miramar, Florida
Cordova Research Institute
Sweetwater, Florida
The Indiana Clinical Trials Center, PC
Plainfield, Indiana
Metro Boston Clinical Partners
Brighton, Massachusetts
J&S Studies, Inc.
New Brighton, Minnesota
JDR Dermatology Research
Las Vegas, Nevada
Tennessee Clinical Research Center
Nashville, Tennessee
DermResearch
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.